The delicate balance between enthusiasm and transparency in small pharmaceutical and biotechnology companies underpins many of the ethical complexities in business communication. These companies often rely on external funding to advance through research and development and must highlight potential breakthroughs to secure investment. Yet, while institutional investors generally have the expertise to evaluate risk, retail investors may rely on overly optimistic headlines or social media commentary. This chapter examines how public announcements, media coverage, and board-level governance shape investor perceptions. It explores the ethical dilemmas faced by executives and boards who aim to sustain enthusiasm while conveying the uncertainties inherent in drug development. It also analyzes the increasing influence of individual shareholders, especially in the aftermath of heightened public attention to biotech stocks, and proposes best practices that foster a culture of honesty and realistic expectations. Through a discussion of real-world scenarios and possible reforms, the chapter underscores how constructive transparency ultimately supports both shareholder value and public trust.